International study of subsequent colorectal cancer among survivors of childhood, adolescent, and young adult cancers (i-scry)

Ended Project Grant Awarded Last action

Award ID
R01CA268143
Recipient
Awarding agency
Obligated
$2,931,292

Award facts

Assistance listing
93.393 Cancer Cause and Prevention Research
Completion date
Originally
Place of performance
New York, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Survivors of childhood, adolescent, and young adult (AYA) cancer have an elevated risk of subsequent malignant neoplasms which are associated with morbidity and premature mortality. Emerging evidence suggests that colorectal cancer (CRC), associated with abdominal or pelvic radiotherapy used to treat the childhood or AYA cancer, is one such neoplasm. Early studies indicate other treatment exposures, including cisplatin and alkylator therapy, may also be associated with CRC risk and may interact with the radiotherapy to confer a markedly elevated risk. Knowledge of whether age at exposure to these therapies might modify risk is limited. Further, prognosis after a treatment-related CRC is not well-understood. These gaps in knowledge are due to the limited number of crcs in any single cohort, lack of detailed information on primary cancer treatments for some cohorts, the relatively young age of cohorts, and the focus of existing cohorts on either childhood cancer survivors or on survivors of specific young adult cancers. We propose to leverage the unique resources of eight international childhood and AYA cancer survivor cohorts. We will pool individual participant data on 51,309 survivors, 298 with CRC, and with median follow-up across studies ranging from 13 to 26 years after primary cancer diagnosis, to comprehensively examine risk factors of, and mortality after, subsequent crcs. This is almost four-fold the number of crcs in any known childhood or AYA cohort with detailed treatment data available. Thus, the combination of childhood and AYA cancer survivors into a single cohort is novel and given common treatment approaches to pediatric and AYA cancer, will enable US to address these questions with the ability to assess the role of age at exposure. The primary aim of this project is to evaluate the association of childhood and AYA cancer therapy (abdominal and/or pelvic radiation fields and dose, as well as chemotherapy exposures including cumulative doses of alkylating agents, anthracyclines, platinating agents) on CRC risk in a large, multi-cohort, international survivor population. Secondary aims will focus on conducting an expanded assessment of the burden of CRC in childhood and AYA cancer survivors. This includes estimating and comparing the incidence of CRC in childhood and AYA cancer survivors to the incidence of CRC in the general population, as well as characterizing mortality following a CRC diagnosis in childhood and AYA cancer survivors and comparing IT to that observed following a DE novo CRC diagnosis in the general population. The results from this work have the potential to help refine screening guidelines and strategies for preventing CRC. In addition, in achieving our aims, we will establish a resource that may be leveraged for future investigator-initiated research.

Transactions

Action Obligated Date
Amendment $0
Amendment $34,635
Amendment $311,715
Amendment $311,715
Amendment $7,087
Amendment $7,087
Amendment $7,087
Amendment $347,269
Amendment $347,269
Amendment $347,269
Amendment $347,269
Amendment $0
Amendment $0
Amendment $0
Amendment $431,445
Original award $431,445
Show all 16

Subawards

Subrecipient Amount Awarded
Prinses Maxima Centrum Voor Kinderoncologie B.V. Leontien Kremer will be responsible for the regulatory aspects and day-to-day supervision of the project and coordination, (legal) administration and completion… $32,336
Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis Dr. van Leeuwen will serve as a close advisor to Drs. Henderson and Moskowitz on all aspects ofthe grant including the harmonization process, the data analysis,… $32,856

Quick answers

Who received award R01CA268143?

R01CA268143 was awarded to Sloan-Kettering Institute For Cancer Research by National Cancer Institute (National Institutes of Health) on February 8, 2022.

How much is award R01CA268143 worth?

$2,931,292 has been obligated on R01CA268143.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login